Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1998;97:119-120

This Article
Right arrow Extract Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rowe, W. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rowe, W. J.

(Circulation. 1998;97:119-120.)
© 1998 American Heart Association, Inc.


Correspondence

The Apollo 15 Space Syndrome

William J. Rowe, MD

Former Assistant Clinical Professor of Medicine, Medical College of Ohio at Toledo

To the Editor:

With the permanent space station planned for the near future and with the recent surge of interest regarding manned missions to Mars, the potential for life-threatening risks looms dead ahead. In 1971 on the Apollo 15 lunar mission, astronauts Irwin and Scott both experienced severe pain and edema of the fingertips.1 In addition, the mission was considered an "anomaly" since it was the first during any space mission distinguished by significant arrhythmias, more severe in Irwin's case with a brief loss of consciousness during an episode of bigeminy after return to the command module.2 Twenty-one months later, Irwin experienced a myocardial infarction.2 It is conceivable that Irwin's infarct was not coincidental but was at least partially triggered by endothelial injuries resulting from the Apollo 15 mission.

In the presence of microgravity, there is invariably a shift of fluid to the upper part of the body. But in addition on the Apollo 15 mission, there was a malfunction of the Insuit water devices, resulting in water deprivation, particularly in Irwin's case during the three extravehicular activities (EVAs) of up to 7 hours each, whereas Scott's Insuit apparatus functioned partially.2 Irwin, sweating profusely and extremely thirsty during the EVAs, lost 5% of his weight compared with his mean preflight weight (from 74.3 to 70.8 kg), whereas Scott lost about half that much (from 81.1 to 78.9 kg).2 This dehydration would have intensified the potential for microgravity-related renin-angiotensin elevations2 and catecholamine elevations,3 with the latter aggravated by pain-provoked sleep deprivation as well.1

Before the Apollo 15 mission, there was a predisposition for a significant magnesium ion deficit, which may persist for several months, since training occurred "in intense summer heat."2 3 This deficit would be compounded by a magnesium deficit secondary to skeletal muscle atrophy resulting from even this brief space mission (12 days).2 This conceivably could predispose to the serious arrhythmias and potassium deficits,2 potential catecholamine elevations with enhanced thrombus formation, and potential endothelial injuries of both peripheral and coronary vessels.3 4

With a water deficit, in addition to compensatory renin-angiotensin elevations,2 there is a loss of protection from increased free radicals (superoxide anions),5 which inactivate nitric oxide6 conducive to endothelial injuries and in turn to vasospasm.3

The Apollo 15 space syndrome, characterized by extremely painful swollen fingertips possibly secondary to peripheral vasospasm and compression by fluid, trapped distally, could serve as a warning that coronary vasospasm (possibly silent3 ) might also exist, predisposing ultimately to a myocardial infarction with4 6 or without3 an associated atherosclerotic plaque rupture, even without radiation effects playing a role.2 7

Finally, this syndrome may be ultimately more common on longer space missions (with invariable angiotensin elevations8 and potential imbalance6 with nitric oxide reductions and more frequent magnesium ion deficits8 ), portending serious endothelial dysfunction.3 Since young women retain magnesium better on marginal magnesium intakes than young men,9 and estrogens have been shown to have several cardiovascular protective effects,10 it is tempting to speculate that young female astronauts are far less likely to experience this syndrome.

References

1. Irwin JB. To Rule the Night: The Discovery Voyage of Astronaut Jim Irwin. Philadelphia, Pa: Holman; 1973:73–74.

2. Johnston RS, Dietlein LF, Berry CA, eds. Biomedical Results of Apollo. Washington, DC: National Aeronautics and Space Administration; 1975:227–264,573–579,581–592. NASA SP-368.

3. Rowe WJ. Extraordinary unremitting endurance exercise and permanent injury to normal heart. Lancet. 1992;340:712–714.[Medline] [Order article via Infotrieve]

4. Hennig B, Toborek M, McClain CJ, Diana JN. Nutritional implications in vascular endothelial cell metabolism. J Am Coll Nutr. 1996;15:345–358.[Abstract]

5. Gutteridge JMC. Biological origin of free radicals, and mechanisms of antioxidant protection. Chem Biol Interact. 1994;91:133–140.[Medline] [Order article via Infotrieve]

6. Gibbons GH. Endothelial function as a determinant of vascular function and structure: a new therapeutic target. Am J Cardiol. 1997;79:3–8.[Medline] [Order article via Infotrieve]

7. Corn BN, Trock BJ, Goodman RL. Irradiation-related ischemic heart disease. J Clin Oncol. 1990;8:741–750.[Abstract]

8. Atkov OY, Bednenko VS. Hypokinesia and Weightlessness: Clinical and Physiologic Aspects. Madison, Wis: International Universities Press; 1992:10–11.

9. Seelig, MS. Increased need for magnesium with the use of combined oestrogen and calcium for osteoporosis treatment. Magnes Res. 1990;3:197–215.[Medline] [Order article via Infotrieve]

10. Kauser K, Rubany GM. Vasculoprotection by estrogen contributes to gender differences in cardiovascular diseases: potential mechanism and role of endothelium. In: Rubany GM, Dzau VJ, eds. The Endothelium in Clinical Practice. New York, NY: Marcel Dekker; 1997:439–467.




This article has been cited by other articles:


Home page
J. Am. Coll. Nutr.Home page
W. J. Rowe
The Case for a Subcutaneous Magnesium Product and Delivery Device for Space Missions
J. Am. Coll. Nutr., October 1, 2004; 23(5): 525S - 528S.
[Abstract] [Full Text] [PDF]


Home page
Journal of Pharmacy PracticeHome page
A. Paskovaty and E. A. O'Rangers
Health Consequences of Spaceflight
Journal of Pharmacy Practice, April 1, 2003; 16(2): 101 - 106.
[Abstract] [PDF]


This Article
Right arrow Extract Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rowe, W. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rowe, W. J.